NOVAVAX INC (NVAX) Stock Fundamental Analysis

NASDAQ:NVAX • US6700024010

9.36 USD
+0.16 (+1.74%)
At close: Feb 23, 2026
9.39 USD
+0.03 (+0.32%)
After Hours: 2/23/2026, 5:43:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to NVAX. NVAX was compared to 521 industry peers in the Biotechnology industry. While NVAX is still in line with the averages on profitability rating, there are concerns on its financial health. NVAX has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • NVAX had positive earnings in the past year.
  • NVAX had a negative operating cash flow in the past year.
  • NVAX had negative earnings in each of the past 5 years.
  • In the past 5 years NVAX reported 4 times negative operating cash flow.
NVAX Yearly Net Income VS EBIT VS OCF VS FCFNVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B

1.2 Ratios

  • With an excellent Return On Assets value of 28.96%, NVAX belongs to the best of the industry, outperforming 98.08% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 43.90%, NVAX belongs to the top of the industry, outperforming 99.42% of the companies in the same industry.
Industry RankSector Rank
ROA 28.96%
ROE N/A
ROIC 43.9%
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NVAX Yearly ROA, ROE, ROICNVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K 5K

1.3 Margins

  • NVAX has a Profit Margin of 32.10%. This is amongst the best in the industry. NVAX outperforms 96.55% of its industry peers.
  • With an excellent Operating Margin value of 39.15%, NVAX belongs to the best of the industry, outperforming 98.46% of the companies in the same industry.
  • NVAX's Gross Margin of 91.82% is amongst the best of the industry. NVAX outperforms 93.47% of its industry peers.
Industry RankSector Rank
OM 39.15%
PM (TTM) 32.1%
GM 91.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVAX Yearly Profit, Operating, Gross MarginsNVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NVAX is creating value.
  • Compared to 1 year ago, NVAX has more shares outstanding
  • Compared to 5 years ago, NVAX has more shares outstanding
  • The debt/assets ratio for NVAX is higher compared to a year ago.
NVAX Yearly Shares OutstandingNVAX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
NVAX Yearly Total Debt VS Total AssetsNVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • Based on the Altman-Z score of -2.15, we must say that NVAX is in the distress zone and has some risk of bankruptcy.
  • NVAX has a Altman-Z score of -2.15. This is comparable to the rest of the industry: NVAX outperforms 50.67% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.15
ROIC/WACC5.12
WACC8.58%
NVAX Yearly LT Debt VS Equity VS FCFNVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M -600M

2.3 Liquidity

  • NVAX has a Current Ratio of 2.27. This indicates that NVAX is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.27, NVAX is not doing good in the industry: 73.70% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.24 indicates that NVAX has no problem at all paying its short term obligations.
  • NVAX has a Quick ratio of 2.24. This is in the lower half of the industry: NVAX underperforms 71.59% of its industry peers.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 2.24
NVAX Yearly Current Assets VS Current LiabilitesNVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 165.04% over the past year.
  • The Revenue has grown by 20.27% in the past year. This is a very strong growth!
  • NVAX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 105.31% yearly.
EPS 1Y (TTM)165.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-64.47%
Revenue 1Y (TTM)20.27%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-16.64%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.51% on average over the next years. This is quite good.
  • Based on estimates for the next years, NVAX will show a very negative growth in Revenue. The Revenue will decrease by -13.97% on average per year.
EPS Next Y234.29%
EPS Next 2Y34.48%
EPS Next 3Y27.21%
EPS Next 5Y17.51%
Revenue Next Year55.16%
Revenue Next 2Y-25.4%
Revenue Next 3Y-26.75%
Revenue Next 5Y-13.97%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NVAX Yearly Revenue VS EstimatesNVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
NVAX Yearly EPS VS EstimatesNVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 6.37, the valuation of NVAX can be described as very cheap.
  • 98.85% of the companies in the same industry are more expensive than NVAX, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of NVAX to the average of the S&P500 Index (26.64), we can say NVAX is valued rather cheaply.
  • NVAX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 6.37
Fwd PE N/A
NVAX Price Earnings VS Forward Price EarningsNVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

  • 99.62% of the companies in the same industry are more expensive than NVAX, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.08
NVAX Per share dataNVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • NVAX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as NVAX's earnings are expected to grow with 27.21% in the coming years.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y34.48%
EPS Next 3Y27.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NOVAVAX INC

NASDAQ:NVAX (2/23/2026, 5:43:16 PM)

After market: 9.39 +0.03 (+0.32%)

9.36

+0.16 (+1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners61.75%
Inst Owner Change7.99%
Ins Owners0.42%
Ins Owner Change4.42%
Market Cap1.52B
Revenue(TTM)1.06B
Net Income(TTM)341.74M
Analysts73.33
Price Target13.15 (40.49%)
Short Float %34.53%
Short Ratio11.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)412.33%
Min EPS beat(2)-3.3%
Max EPS beat(2)827.96%
EPS beat(4)2
Avg EPS beat(4)268.3%
Min EPS beat(4)-58.31%
Max EPS beat(4)827.96%
EPS beat(8)4
Avg EPS beat(8)103.35%
EPS beat(12)7
Avg EPS beat(12)71.73%
EPS beat(16)7
Avg EPS beat(16)-6.56%
Revenue beat(2)2
Avg Revenue beat(2)61.22%
Min Revenue beat(2)58.52%
Max Revenue beat(2)63.92%
Revenue beat(4)4
Avg Revenue beat(4)53.78%
Min Revenue beat(4)2.61%
Max Revenue beat(4)90.08%
Revenue beat(8)5
Avg Revenue beat(8)24.49%
Revenue beat(12)7
Avg Revenue beat(12)22.3%
Revenue beat(16)8
Avg Revenue beat(16)9.73%
PT rev (1m)0.87%
PT rev (3m)-5.4%
EPS NQ rev (1m)-0.56%
EPS NQ rev (3m)-0.07%
EPS NY rev (1m)-3.53%
EPS NY rev (3m)-4.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.37%
Valuation
Industry RankSector Rank
PE 6.37
Fwd PE N/A
P/S 1.43
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 1.08
EPS(TTM)1.47
EY15.71%
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-2.36
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS6.55
BVpS-0.96
TBVpS-1.66
PEG (NY)0.03
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 28.96%
ROE N/A
ROCE 55.58%
ROIC 43.9%
ROICexc N/A
ROICexgc N/A
OM 39.15%
PM (TTM) 32.1%
GM 91.82%
FCFM N/A
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0.54
Cap/Depr 15.47%
Cap/Sales 0.51%
Interest Coverage 19.68
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 2.24
Altman-Z -2.15
F-Score6
WACC8.58%
ROIC/WACC5.12
Cap/Depr(3y)158.98%
Cap/Depr(5y)408.8%
Cap/Sales(3y)4.02%
Cap/Sales(5y)5.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)165.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-64.47%
EPS Next Y234.29%
EPS Next 2Y34.48%
EPS Next 3Y27.21%
EPS Next 5Y17.51%
Revenue 1Y (TTM)20.27%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-16.64%
Revenue Next Year55.16%
Revenue Next 2Y-25.4%
Revenue Next 3Y-26.75%
Revenue Next 5Y-13.97%
EBIT growth 1Y243.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year278.83%
EBIT Next 3Y11.77%
EBIT Next 5YN/A
FCF growth 1Y46.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.24%
OCF growth 3YN/A
OCF growth 5YN/A

NOVAVAX INC / NVAX FAQ

Can you provide the ChartMill fundamental rating for NOVAVAX INC?

ChartMill assigns a fundamental rating of 4 / 10 to NVAX.


What is the valuation status for NVAX stock?

ChartMill assigns a valuation rating of 5 / 10 to NOVAVAX INC (NVAX). This can be considered as Fairly Valued.


How profitable is NOVAVAX INC (NVAX) stock?

NOVAVAX INC (NVAX) has a profitability rating of 4 / 10.


What are the PE and PB ratios of NOVAVAX INC (NVAX) stock?

The Price/Earnings (PE) ratio for NOVAVAX INC (NVAX) is 6.37 and the Price/Book (PB) ratio is -9.71.


Can you provide the financial health for NVAX stock?

The financial health rating of NOVAVAX INC (NVAX) is 3 / 10.